Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (DE:HDP1)
FRANKFURT:HDP1
RESEARCH TOOLSreports
Holding DE:HDP1?
Track your performance easily
HDP1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€15.94 - €36.69
Previous Close€20.51
Volume30.00
Average Volume (3M)128.00
Market Cap
€2.52B
Enterprise Value€2.29B
Total Cash (Recent Filing)$367.27M
Total Debt (Recent Filing)$118.09M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Nov 26, 2024EPS Estimate
-€0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding124,315,274
10 Day Avg. Volume13
30 Day Avg. Volume128
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)7.54
Price to Sales (P/S)136.10
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue116.57
Enterprise Value/Gross Profit9.51
Enterprise Value/Ebitda-4.51
Forecast
1Y Price Target
€40.05Price Target Upside95.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Arrowhead Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe plozasiran pipeline-in-a-drug strategy is underscored by positive Phase III PALISADE study results in familial chylomicronemia syndrome.
Pipeline DevelopmentThe extra-hepatic pipeline expansion shows visible progress in high-value programs like ARO-RAGE, ARO-DM1, ARO-DUX4, and ARO-INHBE.
Strategic FinancingArrowhead Pharmaceuticals announced securing $500M strategic financing facility with flexible 7-year repayment structure, which supports its aggressive pipeline expansion.
Bears Say
Financial PerformanceThe equity sell-off was driven by relatively expensive debt financing coinciding with higher than expected R&D spend.
Operational ExpenditureFrustration mounts with rapid expense growth, including a $50mm quarter-over-quarter increase in R&D spend.
Treatment OutcomesPlozasiran treatment led to a rise in LDL cholesterol, which is not a desired treatment outcome even if triglycerides decrease.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.46% Insiders
20.57% Mutual Funds
5.87% Other Institutional Investors
43.72% Public Companies and
Individual Investors
HDP1 FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was €15.94 and its highest was €36.69 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Currently, no data Available
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Nov 26, 2024 which is in 12 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported -€1.296 earnings per share for the quarter, missing the consensus estimate of -€0.497 by -€0.799.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -€0.91.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 124,315,280 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -€1.296 in its last earnings report, missing expectations of -€0.497. Following the earnings report the stock price went up 3.526%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Among the largest hedge funds holding Arrowhead Pharmaceuticals’s share is Slate Path Capital LP. It holds Arrowhead Pharmaceuticals’s shares valued at 108M.
---
Arrowhead Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€40.05 (95.28% Upside)
€40.05 (95.28% Upside)
Blogger Sentiment
Bullish
DE:HDP1 Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.21%
12-Months-Change
Fundamentals
Return on Equity
-154.92%
Trailing 12-Months
Asset Growth
11.04%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
---
HDP1 Earnings Call
Q3 2024
0:00 / 0:00
---
HDP1 Stock 12 Month Forecast
Average Price Target
€40.05
▲(95.28% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Voyager Therapeutics
―
Best Analysts Covering HDP1
1 Year
1 Year Success Rate
19/37 ratings generated profit
1 Year Average Return
+33.82%
reiterated a buy rating 2 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 51.35% of your transactions generating a profit, with an average return of +33.82% per trade.
---